CompanyOSTXNYSERockville, MD

OS Therapies Inc

OS Therapies develops OST-HER2, a cancer immunotherapy targeting HER2 in osteosarcoma and solid tumors.

SEC EDGAR ClinicalTrials.gov ostherapies.com

424B4Sep 22Latest SEC filing

Sep 9Latest story

September 2026

OS Therapies stockholders back director slate, pay plan changes at 2026 annual meeting

Sep 9PeopleOS Therapies Inc

August 2026

OS Therapies files $75 million at-the-market equity offering with Jefferies

Aug 25FinancingOS Therapies Inc

OS Therapies sets up $75 million at-the-market stock offering with Jefferies

Aug 21PartnershipOS Therapies Inc

OS Therapies details Leonite settlement and $10 million August note financing

Aug 12PartnershipOS Therapies Inc

OS Therapies registers 500,000 shares for Leonite as part of debt settlement

Aug 6FinancingOS Therapies Inc

July 2026

OS Therapies terminates $18 million at-the-market stock sale agreement

Jul 29PartnershipOS Therapies Inc

OS Therapies files Form D for debt offering worth up to $9.25 million

Jul 15FinancingOS Therapies Inc

OS Therapies adds Craig Eagle to board, signs $10 million convertible note deal

Jul 2PeopleOS Therapies Inc